Laidlaw reissued their hold rating on shares of iCAD (NASDAQ:ICAD - Free Report) in a research report report published on Thursday, Marketbeat reports.
ICAD has been the subject of several other research reports. StockNews.com raised iCAD from a "sell" rating to a "hold" rating in a research report on Wednesday, March 26th. BTIG Research lowered shares of iCAD from a "buy" rating to a "neutral" rating in a report on Wednesday, April 16th.
Check Out Our Latest Analysis on ICAD
iCAD Price Performance
iCAD stock traded up $0.11 during trading hours on Thursday, reaching $3.14. The stock had a trading volume of 864,518 shares, compared to its average volume of 363,076. The stock has a market cap of $85.93 million, a PE ratio of -24.12 and a beta of 1.78. The company has a fifty day simple moving average of $2.34 and a 200-day simple moving average of $2.15. iCAD has a 52 week low of $1.18 and a 52 week high of $3.78.
iCAD (NASDAQ:ICAD - Get Free Report) last posted its earnings results on Wednesday, March 19th. The technology company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.02. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%. The firm had revenue of $5.41 million for the quarter, compared to analysts' expectations of $4.72 million.
Institutional Trading of iCAD
Institutional investors have recently bought and sold shares of the company. Granahan Investment Management LLC purchased a new stake in shares of iCAD during the 4th quarter valued at about $96,000. Integrated Wealth Concepts LLC purchased a new position in iCAD during the fourth quarter valued at approximately $92,000. Wells Fargo & Company MN grew its holdings in iCAD by 51.3% during the 4th quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company's stock valued at $72,000 after buying an additional 13,402 shares in the last quarter. Perritt Capital Management Inc lifted its position in shares of iCAD by 1.9% in the fourth quarter. Perritt Capital Management Inc now owns 189,100 shares of the technology company's stock worth $346,000 after buying an additional 3,600 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in iCAD by 6.6% during the fourth quarter. Geode Capital Management LLC now owns 276,493 shares of the technology company's stock valued at $506,000 after buying an additional 17,059 shares during the last quarter. 24.61% of the stock is owned by hedge funds and other institutional investors.
About iCAD
(
Get Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Featured Stories
Before you consider iCAD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iCAD wasn't on the list.
While iCAD currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
